GainersToday.com
GainersToday.com, Tracking Stock Market Picks
Enter Symbol:
Rating: MDVN
Buy $180

MEDIVATION INC (NASDAQ: MDVN) reiterated to Buy with price target $180 by Canaccord Genuity

Wednesday,  Apr 8, 2015  9:25 AM ET by Lynn Gilbert

Canaccord Genuity reiterated MEDIVATION INC (NASDAQ: MDVN) to Buy with price target
$180. Previously, Canaccord Genuity rated MEDIVATION INC (NASDAQ: MDVN) to Buy with price target $132 on 09/18/2014, when the stock price was valued at $99.80.

Medivation, Inc. is a biopharmaceutical company with small molecule drugs in clinical development to treat three medical needs: Alzheimer?s disease, Huntington?s disease and castration-resistant prostate cancer. The Company has formed separate subsidiaries to hold the product candidates it is developing. The Company?s subsidiary Medivation Neurology, Inc. holds its Dimebon technology, and its subsidiary Medivation Prostate Therapeutics, Inc. holds its MDV300 series technology.

Canaccord Genuity’s global team of over 100 research professionals are inquisitive, experienced and committed to generating actionable investment ideas. We analyze over 725 companies in a broad range of market sectors, identifying value and defining risk for our clients.



RSS Feed | |  Facebook |  Twitter |  Google Plus
Home | Terms of Use | Advertise | FAQ | Support Page | Contact Us | About Us | Privacy Policy